O-1871
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 620964-96-7 |
PubChem (CID) | 10405368 |
ChemSpider | 8580806 |
Chemical and physical data | |
Formula | C23H38O2 |
Molar mass | 346.55 g/mol |
3D model (Jmol) | Interactive image |
| |
|
O-1871 is a potent cannabinoid agonist which was invented by Billy R Martin and Raj K Razdan in 2002. It has a CB1 receptor affinity of 2.0nM and a CB2 receptor affinity of 0.3nM.[1] Structurally, O-1871 is a cyclohexylphenol derivative related to CP 47,497, and so is illegal in most jurisdictions where CP 47,497 and its derivatives are banned. However the 3,3-dimethylcyclohexyl substituent of O-1871 can be replaced by various other groups, producing other potent compounds such as the cycloheptyl derivative O-1656 and the 2-adamantyl derivative O-1660, as well as the corresponding 3,5-dichlorophenyl derivative,[2] which are not cyclohexylphenol derivatives.
See also
References
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.